Clin Cancer Res. 2022 Dec 9:CCR-22-2400. doi: 10.1158/1078-0432.CCR-22-2400. Online ahead of print.
NO ABSTRACT
PMID:36485007 | DOI:10.1158/1078-0432.CCR-22-2400
Categories
FDA Approval Summary: Ripretinib for advanced gastrointestinal stromal tumor
